drugset / Trial / NCT01247194
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-05
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PPI-461 | Unknown | 50 mg | Oral |
| Comparator | PPI-461 | Unknown | 100 mg | Oral |
| Comparator | PPI-461 | Unknown | 200 mg | Oral |